Table 2.
Treatment outcomes.
| Patient | Sex | Age | Site of Lesions | Survival (Months) |
Time to Progression (Months) |
Best Response | Reason for Discontinuation | Adverse Effects | Subsequent Therapy |
|---|---|---|---|---|---|---|---|---|---|
| 1 # | M | 74 | liver | 23.6 * | NR | SD | NA (ongoing) | - | NA |
| 2 # | F | 82 | liver | 17.7 | 6.2 | SD | PD | hypothyroidism (G2) | capecitabine |
| 3 # | F | 56 | liver, peritoneum, lymph nodes, bone | 2.7 | 2.2 | PD | PD | pneumonia (G3) | - |
| 4 # | M | 66 | liver, bone | 8.4 | 4.4 | SD | PD | skin (G1) | - |
| 5 | M | 57 | liver, lung, peritoneum, bone | 29.1 * | NR | PR | NA (ongoing) | - | NA |
| 6 | M | 66 | liver, lung | 5.7 | 3.1 | PD | PD | - | - |
| 7 | M | 74 | liver, lung | 9.5 | 8.3 | SD | PD | pneumonia (G1) | - |
| 8 | M | 69 | liver, peritoneum | 16.3 | 9.6 | SD | PD | - | clinical trial |
| 9 | M | 65 | liver, peritoneum, soft tissues | 15.5 * | NR | SD | NA (ongoing) | - | NA |
| 10 | M | 66 | liver, lung, peritoneum | § | 1.7 | PD | COVID-19 | - | § |
# Patient with peripheral blood mononuclear cell (PBMC) collection. * Partial data (patient alive). § Lost to follow-up. M, male; F, female; NR, progression not reached; NA, not applicable; PR, partial response; SD, stable disease; PD, progressive disease; G, grade.